Protein kinase C inhibitors

Details Protein kinase C inhibitors Protein kinase C inhibitors

1995-05-25

1997-08-26

Chang, Ceila

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514214, 514269, 514272, 514323, 514339, 514411, 514415, A61K 3140, C07D40314

Patent

active

056611730

ABSTRACT:
The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.

REFERENCES:
patent: 4785085 (1988-11-01), Kaneko et al.
patent: 4808613 (1989-02-01), Kaneko et al.
patent: 4923986 (1990-05-01), Murakata et al.
patent: 5057614 (1991-10-01), Davis et al.
patent: 5292747 (1994-03-01), Davis et al.
patent: 5380746 (1995-01-01), Barth et al.
Bradshaw et al. "Therapeutic potential of protein kinase C inhibitors" Agents Actions v.38, pp. 135-147 (1993).
Thomas et al. "Dioctanoylglycerol regulation of sytosolic Ca by protein kinase C independent mechanism in HIT T-15 islet cells" Diabetes v.40, pp. 621-627 (1991).
Zetterstrom et al. "Differential expression of retinal insulin receptors in STZ-induced diabetic rats" Diabetes vol. 41 pp. 818-825 (1992).
Xia et al. "Identification of the mechanism for the inhibition of Na, K adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2" J. Clin. Invest. v.96, pp. 733-740 (1995).
Derwent Abstract 92-274042/33;90.11.20 90JP-314628 (1992).
Meier, et al., Tetrahedron Letters, 34:33, 5277-5280 (1993).
Wilkinson, et al., Bichem. J., 294, 335-337 (1993).
Bit, et al., J. Med. Chem., 36, 21-29 (1993).
Martiny-Baron, et al., The Journal of Biological Chemistry, 268:13, 9194-9197 (1993).
Krakowiak, et al, SYNLETT, 611-620, (Sep. 1993).
Mulqueen, et al., Agents Actions, 37, 85-89 (1992).
Davis, et al., J. Med. Chem., 35, 177-184 (1992).
Davis, et al., J. Med. Chem., 35, 994-1001 (1992).
Toullec, et al., The Journal of Biological Chemistry, 266:24, 15771-15781 (1991).
Nixon, et al., Drugs Exptl. Clin. Res., 17:8, 389-393 (1991).
Davis, et al., Tetrahedron Letters, 31:36, 5201-5204 (1990).
Brenner, et al., Tetrahedron Letters, 44:10, 2887-2892 (1988).
Joyce, et al., The Journal of Organic Chemistry, 52:7, 1177-1186 (1987).
Buchdunger, et al., Proc. Natl. Acad. Sci. USA, 91, 2334-2338 (Mar. 1994).
Kobayashi, et al., The American Physiological Society, 0363-6135, H1214-H1220 (1994).
Felsenstein, et al., Neuroscience Letters, 174 173-176 (1994).
Demaerschalck, et al., Biochimica et Biophysica Acta, 1181 214-218 (1993).
Shimohama, et al., Neurology, 43 1407-1413 (1993).
Derwent Abstract 90-1329471/18; Oct. 21, 1988-DE-835842.

Affiliated with

Also associated with

Rating

Protein kinase C inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protein kinase C inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase C inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1988843